Alirocumab (Praluent) reduced LDL by up to 62% and cut major cardiovascular events by 15% post-ACS in the ODYSSEY Outcomes trial, with the greatest benefit seen in patients with the highest baseline LDL.
Research summaries are AI-generated from open-access peer-reviewed literature (PubMed Central, Cochrane, AHA/ACC). Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.